M28 Capital Management’s Rocket Pharmaceuticals RCKT Stock Holding History

M28 Capital Management’s Portfolio RCKT Stock Details RCKT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$555K	Hold	210,871	–	–	1.54%	8
2026 Q2	$721K	Hold	210,871	–	–	1.53%	8
2026 Q1	$755K	Sell	210,871 -174,809	-45%	-$695K	1.4%	7
2025 Q4	$1.35M	Hold	385,680	–	–	0.98%	7
2025 Q3	$1.26M	Hold	385,680	–	–	1.85%	7
2025 Q2	$945K	Hold	385,680	–	–	1.61%	9
2025 Q1	$2.57M	Hold	385,680	–	–	3.53%	5
2024 Q4	$4.85M	Hold	385,680	–	–	4.76%	3
2024 Q3	$7.12M	Hold	385,680	–	–	7.83%	3
2024 Q2	$8.3M	Hold	385,680	–	–	10.76%	3
2024 Q1	$10.4M	Sell	385,680 -137,600	-26%	-$3.91M	7.68%	4
2023 Q4	$15.7M	Hold	523,280	–	–	12.99%	3
2023 Q3	$10.7M	Sell	523,280 -107,100	-17%	-$1.95M	12.3%	3
2023 Q2	$12.5M	Sell	630,380 -91,700	-13%	-$1.85M	16.55%	2
2023 Q1	$12.4M	Hold	722,080	–	–	13.99%	2
2022 Q4	$14.1M	Buy	722,080 +56,200	+8%	+$1.03M	13.47%	2
2022 Q3	$10.6M	Sell	665,880 -50,000	-7%	-$780K	11.09%	3
2022 Q2	$9.9M	Hold	715,880	–	–	11.04%	3
2022 Q1	$11.4M	Buy	715,880 +220,600	+45%	+$3.81M	10.44%	3
2021 Q4	$10.8M	Buy	+495,280	New	+$13.5M	8.44%	5

Other funds holding RCKT

BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return

Citigroup New York $308B AUM 40.94% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM

Marshall Wace London, United Kingdom $114B AUM 35.47% 1-Year Est. Return

Monaco Asset Management Monaco $818M AUM 32.61% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM

M28 Capital Management's RCKT Position: Q3 2026 in Review

M28 Capital Management held its Rocket Pharmaceuticals (RCKT) position steady in Q3 2026 at 210,871 shares worth $555K. The position accounts for 1.54% of the portfolio, ranked #8.

M28 Capital Management first reported a position in RCKT in Q4 2021 and has held it in 20 quarters since. The position peaked at $15.7M in Q4 2023. 116 funds tracked by Wall St. Rank hold RCKT as of Q3 2026.

M28 Capital Management held 210,871 shares of Rocket Pharmaceuticals worth $555K as of Q3 2026.
M28 Capital Management left its Rocket Pharmaceuticals share count unchanged in Q3 2026.
Rocket Pharmaceuticals made up 1.54% of M28 Capital Management's portfolio in Q3 2026, its #8 holding.
M28 Capital Management first reported a position in Rocket Pharmaceuticals in Q4 2021 and has held it in 20 quarters since.
M28 Capital Management's Rocket Pharmaceuticals position peaked at $15.7M in Q4 2023.
116 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2026.

Based on M28 Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.